Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion

Anti-Cancer Drugs

Volumn 16, Issue 1, 2005, Pages 11-19

  Woodward, Julia K L ^a,b   Coleman, Robert E ^a   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adhesion; Bisphosphonates; Breast cancer; Cytotoxic drugs; Invasion; Metastatic bone disease; Mevalonate pathway; Migration; Prostate cancer

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOTOXIC AGENT; DOXORUBICIN; FARNESOL; GERANYLGERANIOL; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IBANDRONIC ACID; OLPADRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RISEDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR MATRIX; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASMS;

EID: 12544251417     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200501000-00002     Document Type: Review

References (64)

1. Sugarbaker EV, Ketcham AS. Mechanisms and prevention of cancer dissemination, an overview. Semin Oncol 1977; 4:19-32.
2. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms, origins and implications. Science 1982; 217:998-1003.
3. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000; 190:310-329.
4. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 2003; 189:117-128.
5. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004; 14:105-114.
6. Keely PJ, Rusyn EV, Cox AD, Parise LV. R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells. J Cell Biol 1999; 145:1077-1088.
7. Van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60:5832-5838.
8. Van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 2002; 1:575-583.
9. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res 2002; 84:57-80.
10. Jo M, Thomas KS, Somlyo AV, Somlyo AP, Gonias SL. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J Biol Chem 2002; 277:12479-12485.
11. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003; 88: 1631-1640.
12. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63:1981-1989.
13. Ali SM, Harvey HA, Lipton A. Metastatic breast cancer, overview of treatment. Clin Orthop 2003; 415(suppl):S132-S137.
14. Sato M, Gransser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88:2095-2105.
15. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42:1228-1236.
16. Orr FW, Lee J, Duivenvoorden WC, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer 2000b; 88(12 suppl):2912-2918.
17. Fromigue O, Kheddoumi N, Body JJ. Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer 2003; 89:178-184.
18. Kostenuik PJ, Singh G, Suyama KL, Orr FW. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clin Exp Metastasis 1992; 10:411-418.
19. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells, evidence for synergy with paclitaxel. Br J Cancer 2001; 84:1126-1134.
20. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82:1459-1468.
21. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170:246-245.
22. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15:2211-2221.
23. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002; 86:1479-1486.
24. Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996; 16:116-131.
25. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83:263-269.
26. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1:27-39.
27. Lowik CW, van der Pluijm G, van der Wee-Pals LJ, van Treslong-De Groot HB, Bijvoet OL. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts, the effect of a bisphosphonate. J Bone Miner Res 1988; 3:185-192.
28. Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998; 63:230-235.
29. Van der Pluijm G, Vloedgraven H, van Seek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98:698-705.
30. Van der Pluijm G, Vloedgraven HJ, Ivanov B, Robey FA, Grzesik WJ, Robey PG, et al. Bone sialoproiein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res 1996; 56:1948-1955.
31. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-3894.
32. Guan JL. Cell biology. Integrins, rafts, Rac, and Rho, Science 2004; 303:773-774.
33. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death, evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278:43603-43614.
34. Kitazawa S, Maeda S. Development of skeletal metastases. Clin Orthop 1995; 312:45-50.
35. 3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002; 16:1266-1268.
36. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60:2949-2954.
37. Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyi transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 2001; 276:48213-48222.
38. Imamura H, Takaishi K, Nakano K, Kodama A, Oishi H, Shiozaki H, et al. Rho and Rab small G proteins coordinately reorganize stress fibers and focal adhesions in MDCK cells. Mol Biol Cell 1998; 9:2561-2575.
39. Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998; 16:693-702.
40. Heikkila P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13:245-254.
41. Heikkila P, Teronen O, Him MY, Sorsa T, Tervahartiala T, Salo T, et al. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J Surg Res 2003; 111:45-52.
42. Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004; 42:410-415.
43. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-2714.
44. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, et al. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 1999; 878:453-65.
45. Andela VB. Correspondence. Re S. S. Virtanen et at. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-27014. Re K. Sawada et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2004; 64: 2934-2935; author reply 2935-2936.
46. Andela VB. Correspondence. Re S. S. Virtanen et at. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-27014. Re K. Sawada et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2004; 64: 2934-2935; author reply 2935-2936.
47. Clezardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antilumor effects of bisphosphonates. Curr Med Chem 2003; 10:173-180.
48. Valleala H, Hanemaaijer R, Mandelin J, Salminen A, Teronen O, Monkkonen J, et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/ macrophages by two different types of bisphosphonates. Life Sci 2003; 73:2413-2420.
49. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002; 62:6015-6020.
50. Muller A, Homey B, Solo H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-56.
51. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62:1832-1837.
52. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
53. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients, 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19:10-17.
54. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20:3219-3224.
55. Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR, Yoneda T. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002; 75:249-258.
56. Stearns ME, Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992; 52:3776-3781.
57. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paditaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003; 104:121-129.
58. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, et al. Proliferation, migration and invasion of human glioma cells exposed to paditaxel (Taxol) in vitro. Br J Cancer 1997; 75:1744-1752.
59. Wang F, Cao Y, Liu HY, Xu SF, Han R. Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells. J Asian Nat Prod Res 2003; 5:121-129.
60. Westerlund A, Hujanen E, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T. Ovarian cancer cell invasion is inhibited by paditaxel. Clin Exp Metastasis 1997; 15:318-328.
61. Benbow U, Maitra R. Hamilton JW, Brinckerhoff CE. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin. Clin Cancer Res 1999; 5:203-208.
62. Sliva D, Harvey K, Mason R, Lloyd Jr F, English D. Effect of phosphatidic acid on human breast cancer cells exposed to doxorubicin. Cancer Invest 2001; 19:783-790.
63. Belotti D, Rieppe M, Nicoletti MI, Casazza AM, Fojo T, Taraboletti G, Giavazzi R, Paditaxel (Taxol inhibits motility of paditaxel-resistant human ovarian carcinoma cells. Clin Cancer Res 1996; 2:1725-1730.
64. Pickering LM, Macdonald CD, Coxon JP, Mansi JL, Colston KW. Zoledronic acid inhibits adhesion of breast cancer cells to protein matrices in a caspase dependent manner [Abstract]. Bone 2004; 24:38.